Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Oncology (Williston Park, N.Y.)|June 24, 2010
Quality-adjusted life-years, comparative effectiveness in cancer care, and measuring outcomes in the underservedKerry L KilbridgeJournal of Women'S Health (2002)|November 2, 2010
Implications of mobility impairment on the diagnosis and treatment of breast cancerLisa I Iezzoni, Elyse R Park, Kerry L KilbridgeAmerican Journal of Preventive Medicine|December 21, 2020
The Relationship Between Health Literacy and Nonrecommended Cancer ScreeningMadeline C Rutan, Jesse D Sammon, David-Dan Nguyen, et al.Eclinicalmedicine|July 26, 2021
Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance studyEugene B Cone, Stephen Reese, Maya Marchese, et al.JMIR Mhealth and Uhealth|November 3, 2020
Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability StudyJunaid Nabi, Eugene B Cone, Anjali Vasavada, et al.Journal of Clinical Epidemiology|June 16, 2004
Hospital discharge abstract data on comorbidity improved the prediction of death among patients hospitalized with aspiration pneumoniaGeorge J Stukenborg, Douglas P Wagner, Frank E Harrell, et al.American Journal of Clinical Oncology|June 3, 2021
Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare DataKarl H Tully, Eugene B Cone, Alexander P Cole, et al.Journal of the National Medical Association|December 14, 2004
Comorbid disease and the effect of race and ethnicity on in-hospital mortality from aspiration pneumoniaM Norman Oliver, George J Stukenborg, Douglas P Wagner, et al.Annals of Surgical Oncology|December 19, 2019
Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate CancerDavid F Friedlander, Marieke J Krimphove, Alexander P Cole, et al.Prostate Cancer and Prostatic Diseases|October 28, 2025
Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancerAutumn Gagnon, Caiwei Zhong, Wanling Xie, et al.Pageof 4